Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Allbirds Inc (BIRD) vs Novo Nordisk A/S (NVO) Price & Performance

Allbirds IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Allbirds Inc vs Novo Nordisk A/S — how do they compare? Allbirds Inc trades at $2.57 (market cap $30.00M), while Novo Nordisk A/S trades at $46.45 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 6928.3× Allbirds Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Allbirds Inc pays none. Which is the better fit depends on your goals.

BIRDNVO
Market Cap
$30.00M$207.85B
Sector
Consumer CyclicalHealth
52-Week High
$16.99$63.98
52-Week Low
$2.21$35.29
Enterprise Value
$48.86M$222.55B
Dividend Yield
3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Allbirds Inc

BIRD (Smartbird) trades at $2.56, down 0.78% on the day, as the company completes its pivot from footwear to AI infrastructure. Despite negative profitability metrics and declining revenue trends, the stock has shown volatility following recent strategic announcements including a name change and new CEO appointment. Technical indicators show mixed signals with a bullish overall rating but bearish moving averages, while fundamental challenges persist with negative net income margins and cash flow concerns.

The outlook remains speculative as BIRD transitions to AI infrastructure, creating both opportunity and significant risk. While analyst sentiment leans cautious with 79% hold ratings, recent leadership changes and strategic pivot could drive future growth if execution improves. Key risks include sustained cash burn, competitive AI market pressures, and the challenge of establishing credibility in a new industry segment.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.

Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Allbirds Inc

Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.

Read more on BIRD

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO